Nanosonics Limited (NAN) Earnings Call Transcript
February 20, 2025
Earnings Call Speaker Segments
We appreciate everyone joining us and welcome you to Nanosonics Limited’s 2025 Half-Year Results. Everyone is currently in listen-only mode. After a presentation, we’ll hold a question-and-answer session. <<operator_script>>. At this point, I’ll turn the conference over to Mr. Michael Kavanagh, Managing Director and CEO. Please go ahead.
Thank you so much, and good morning everyone — appreciate you all being on the call. I'm aware today is a busy one in the markets. Jason Burriss, our CFO, is with me today, and he'll walk you through the details of the financial results shortly, but I'd like to make a few comments first. As you'll have seen, the half year results put out this morning confirm the figures in the trading update we issued roughly four weeks back, toward the end of January. First half revenue came in at AUD 93.6 million, which is a good start to the year — 18% higher than the prior corresponding period, and, importantly, also 4% above the very strong second half we delivered in FY 2024. All in all, I was very pleased with how the business performed operationally across the board in the first half. Given that positive start, and having reviewed our internal forecast for the second half, you'll have noticed we've lifted our full year revenue growth range from 8% to 12% to 11% to 14%. That assumes the same FX rate of $0.67 at which the original guidance was set.
Naturally, FX isn’t sitting at those levels right now. If we translated this guidance using a lower FX rate of roughly $0.64 for the second half, then that 11% to 14% revenue growth would come out at approximately 13% to 16% growth. So, as you’re aware, we’re getting some tailwinds from FX in the second half relative to the actual guidance. Before I hand things over to Jason, there are a couple of key points I’d take from the first-half outcome. First, our North American business is still performing very well, with trophon continuing to consolidate its position as standard of care. But importantly, our growth strategy for North America remains on track and is very clear. For capital unit growth, it’s very much about continuing to grow the install base. And in the first half, that grew by 940 units, with over 31,000 units now in operation across thousands of facilities in North America. And this new install base growth—what we had in the first half, as well as what we anticipate in the second half—is coming from both the hospital and the private physician market, where we do have specific strategies in place for both segments.
We anticipate comparable new IB figures for the second half as we saw in the first half. That gives us solid cumulative expansion in the total installed base across North America. Still on capital growth: upgrades remain a meaningful opportunity for us, since more than 10,000 first generation trophon EPR units are still in operation today. That figure is for North America. During the first half, we recorded 610 upgrades, which represents growth over PCP. Given a strong pipeline, we anticipate fairly healthy growth in that number for the second half. Shifting from capital to annuity revenue growth, or recurring revenue: a central pillar of our North American growth strategy is customer value expansion, and making trophon the standard of care in North America means we already have a substantial install base in operation. As I noted earlier, that's 31,000 units spanning thousands of facilities. This sizable install base clearly gives us the chance to deliver and expand customer value, and as a result, an opportunity for robust annuity revenue growth. Now, where does this expanded customer value come from? There are several elements. The first is continued education. We have an excellent clinical applications team in North America, and ongoing education from that team for our customers ensures there is understanding of all the various types of ultrasound procedures that require high-level disinfection.
Naturally, that can drive additional consumables growth as more patients receive protection. Ultrasound itself, as a clinical modality, is of course expanding, and that raises the number of procedures potentially needing high-level disinfection. We did observe an increase in total ultrasound procedures across North America. And from one of the big OEMs that reported overnight, I saw they likewise mentioned growth in overall ultrasound procedure volumes taking place in North America. Then beyond the CORIS disinfectant consumables, there is the wider ecosystem of consumables involved in the reprocessing workflow. That covers cleaning and drying wipes along with clean probe covers, which get used once the probe has been decontaminated. That matters, because it keeps the probe from becoming recontaminated prior to use. So products along those lines, and we are seeing solid growth in those offerings too. We definitely anticipate growth, and we are placing somewhat more emphasis on our digital traceability solutions, which performed reasonably in the first half, and we expect continued growth there in the second half and beyond. In addition, a rapidly expanding part of our business is our technical service, delivered through service contracts or pay-as-you-go service. That represents a fast-growing piece of the annuity revenue, along with supplying service parts to GE Healthcare, which keeps providing service in North America for a great many of all the original first generation units that they sold initially.
And it's worth pointing out there that the increase in upgrades we expect is also a key factor behind new service contract growth for Nanosonics direct, since most of those upgrades involve older machines that GE Healthcare originally sold. Yet upgrades are sold only by Nanosonics. And when we make that sale, well, we then also sell the service contracts for the upgrades too. So we see a big opportunity for ongoing growth, and strong growth, in customer value expansion. And in fact, during the first half we saw some solid growth in annuity revenue across all the dimensions I mentioned, with consumable service revenue in North America rising 19% in the half. And just briefly, still in North America, we're also growing our infrastructure there so we can begin consumables manufacturing at our Indianapolis site, and those will be consumables for both trophon and CORIS, and that ought to be operational by the end of this financial year. And this delivers a number of benefits. Over time there will be some margin improvements on these consumables. Importantly, there are sustainability benefits, since lower transport requirements result from being closer to the customer.
Also, I believe this lessens our exposure to the possibility of tariffs being introduced. And on the whole, our exposure is fairly limited, though this does enhance our position in that respect too by lowering that exposure. So overall, North America is definitely still performing strongly, with a substantial opportunity for continued growth, and we anticipate part of that growth showing up in the second half. Turning to our European region, we stay confident about the growth opportunity overall in that region. Revenue for the half was up 37% versus PCP, which came to AUD 5.9 million. Our new installed base was slower than expected in H1, with 70 units installed. That said, we think part of this was phasing. Given the active pipeline, we do expect stronger performance in H2. And as you're aware, this region is complex, with various markets at differing stages when it comes to adoption fundamentals. And our near-term focus is on prioritizing those markets with the strongest fundamentals, specifically the UK, Ireland and a number of distributor markets. And like North America, our aim is likewise to grow customer value among the roughly 2,300 install base already in place. So that's where we keep driving annuity revenue growth.
We also observed solid growth in annuity revenue for the first half compared with PCP, rising to AUD 1.2 million this year from AUD 0.7 million. One more element we have incorporated into our European strategy — and I brought this up at the close of last year's financial year — is that, given the infrastructure we already possess and the sales infrastructure we already possess, we should leverage our direct infrastructure together with third-party products that make sense for us. We now hold an exclusive distribution agreement for the Eco Lab TEE disinfection system for cardiac ultrasound, and that is highly complementary to trophon. These cardiac ultrasounds are, in a sense, somewhat like endoscopes, though without <<inaudible>>, since they are long and flexible and inserted into the body — in this case down the esophagus for cardiac imaging — but they do call for a different approach to high-level disinfection, somewhat more like a washer disinfector, which is what the Eco Lab product provides. So, similar to trophon, it has capital and consumable service components, so very similar from that standpoint. And in APAC, which, as you know, today is primarily ANZ, as you know, this market is quite penetrated with trophon as the standard of care.
For the half, revenue came in at the same level as PCP. Capital revenue did decline, although a 14% rise in recurring annuity revenue made up for it. There was definitely some phasing tied to capital growth during the first half, and we do expect — and have forecast — half-on-half growth in new installed base and in total units overall, along with additional annuity revenue growth from the existing IB in H2. In Japan, our focus outside of ANZ within APAC, we are continuing our market development work. Early adopter sales are rising in H1 as awareness keeps building. The guidelines remain absent, and we are still working toward them. Importantly, we have just finished another study in Japan that not only confirms and shows the high degree of contamination on probes — in this case specifically in emergency care — but also showed that the current practice of wiping with ethanol wipes or alcohol wipes does not work, whereas trophon proved 100% effective. So once again, we keep building all the clinical evidence and then get that evidence leveraged with the various societies and opinion leaders in Japan. But pleasingly, we are now starting to see some sales traction in Japan as awareness grows.
With those strategies now deployed across the regions, we expect growth in all three during the second half, which underpins the increase to our revenue guidance. A few other quick items, then I'll pass it to Jason. As in the past several reports, the release this morning includes a P&L for the trophon-only business. That provides a solid view of how the trophon-only business is performing and its profitability, because it strips out every investment not currently producing revenue outside trophon, including CORIS and R&D unrelated to trophon. It is worth noting, though, that we have allocated several one-off investments into this trophon P&L, among them our spending on the new ERP system. You will see that the trophon-only business delivered strong profitability in the first. Profit before tax of AUD 25.6 million. More importantly, operating leverage grew positively, with PBT as a share of revenue rising from 23% to 27%. And in fact, excluding the one-off ERP expenses, which come to roughly AUD 1.8 million — close to AUD 2 million — that operating leverage would have been nearer 30%. So the trophon business has good profitability, and good leverage is coming through in the trophon business.
And then, to wrap up, our confidence in what CORIS can do for endoscope reprocessing remains strong. It's still moving through the FDA's de novo review. When we last spoke, I noted that the FDA had sent us a substantial number of questions. We've now submitted our responses to the questions received from the FDA so far. As we said in this morning's release, we're continuing to get our supply chain and manufacturing ready, and we're still aiming to begin the first stage of commercialization in Q1 of FY 2026, assuming, of course, that we get the regulatory approvals we need. Now, if the FDA grants de novo clearance for the CORIS system, marketing of the device will begin in the US. At the same time, we expect to submit the first 510(k) for expanded scope indications soon after that. As I said, over time, following a de novo approval, we'll file for expanded indications so that we can cover the wide range of endoscopes in use on the market. Outside the US, though, the first commercial launch will probably happen in Europe. That's also Q1 FY 2026, and it doesn't depend on the FDA de novo clearance.
With that said, I'll pass things over to Jason, who will walk through some specifics on the financials.
Thanks, Michael. And good morning, everyone. As Michael mentioned earlier, total revenue for the half came in at AUD 93.6 million, which is up 18% versus the prior corresponding period, with growth across capital, consumables and service. Starting with capital revenue, it rose 11% to AUD 22.7 million in the first half. We sold a total of 1,730 units during the half, roughly in line with the prior corresponding period. The revenue increase was mainly driven by the mix of unit volumes across regions, with more units sold through our direct operation in North America and more units sold as a capital sale rather than MES in Europe. You'll recall that we don't get revenue upfront for an MES product in Europe. Instead, we receive higher consumables revenue over time. Pricing on capital units stayed relatively steady during the half. Moving to consumables and service revenue, growth there was 20% for the first half, reaching AUD 62 million. A few factors drove this. First, a higher installed base year-on-year, and second, increasing ultrasound procedures, which were up about 7% over the first half of 2024. That held consumables volume. And the customer value expansion activities Michael mentioned earlier, including technical service and sales of our ecosystem products, also grew and contributed to that 20% growth in consumables and service revenue for the half.
Technical service remains a rapidly expanding part of our business, driven by greater uptake of technical service contracts as the installed base and upgrade volumes increase. On the balance sheet you'll notice contract liabilities rose roughly 11% to about AUD 30 million, and the bulk of that relates to prepaid multi-year service contracts, which clearly also benefits our cash position. Turning to margin, gross profit margin came in at 78.5% for the half, sitting inside the range we anticipate. Happily, that margin was up from 76.3% in the second half of 2024, which, as you'll recall, was mainly because manufacturing slowed while we began an inventory reduction program. That program worked, bringing inventory levels down by approximately AUD 5 million, or 20%. We are now producing at normal volumes again and expect to deliver a full-year margin similar to the half, at around 78.5%. Now to costs: we have disciplined cost control measures running throughout the business, and we see that in operating expenses growing more slowly than revenue. OpEx climbed 10% while revenue grew 18%. Operating expenses for the half totaled AUD 66.7 million, which, as I mentioned, was about 10% above the prior corresponding period and roughly 3% above the second half of last year.
The biggest single factor behind that increase was roughly AUD 1.8 million of spending on the new ERP implementation and associated costs during the half. We expect the ERP to go live in late fiscal year 2025, and most of those costs are one-off in nature and won't recur in fiscal year 2026. The second-largest driver of operating expenses was staffing costs tied to inflation, along with higher sales commissions stemming from stronger business performance in North America. It's worth highlighting R&D, which as you know we expense in full. We remain committed to ongoing R&D and, as we've said before, we anticipate going forward that although R&D investments will probably rise, they will decline over time as a percentage of revenue. We're seeing that in the first half. R&D expense fell from 20% of revenue in the prior corresponding period to 17% in the first half results. This disciplined approach to operating expenses will continue, with particular focus on making sure the trophon business further builds the positive operating leverage we have established. That leads us to operating profit. Happily, operating profit before income tax came in at AUD 10.9 million, up 124% versus the prior period's AUD 4.9 million. Although the main driver was 18% revenue growth, our diligent approach to margins and cost management made sure those benefits reached the bottom line.
We delivered a positive operating result. As we mentioned in our earlier trading update, the half one result does include an unrealized foreign exchange gain of approximately AUD 1.3 million. That comes from the exchange rate moving from around $0.66 on the 30th of June to $0.62 on the 31st of December 2024. We saw that sharp fall in December. This compared to a loss of around AUD 0.4 million in the first half of 2024. Setting that FX component aside, PBT was still 81% higher than the first half of 2024. A brief comment on tax, income tax. With the business doubling its profit before tax, tax expense moved from a benefit position to an expense. The tax expense was AUD 1.1 million in the first half versus a benefit of AUD 1.3 million in the first half of 2024. The effective income tax rate was 10.5% in the first half of 2025. This meant net profit for the half was AUD 9.8 million, 58% higher than the first half of 2024, AUD 6.2 million. And just lastly, before I hand back to Michael, a word on cash flow, the business generated AUD 13.8 million in cash flow for the half, leading to a cash balance of AUD 144.5 million.
Just to remind everyone, there is no debt on the company's books. With that said, Michael, I'll turn things back over to you.
Thanks, Jason. So, taking a step back, as I mentioned at the start, it was a positive half across the board, but more importantly, looking at expectations, we anticipate additional growth in all three regions during the second half. As a result, and as we've already noted, this has driven an increase in our full-year revenue guidance, taking it from 8% to 12% up to 11% to 14%. We've also tightened the range on gross margin guidance, from 77% to 79%, bringing it to 78% to 79%. As Jason mentioned, we're expecting something in the middle of that, roughly 78.5% percent or so. The OpEx range has likewise been refined, shifting from 6% to 10% to approximately 8% to 10%, and the raise at the bottom end of that range stems mainly from the higher sales we're anticipating and, as a result, greater sales commissions and so on. With that, thanks for listening, and we'll now open things up for any questions.
We’ll take our first question from Josh K at Barrenjoey.
I have a couple of questions. The first is just about consumables and service revenue. Obviously, that came in pretty high. I understand we've discussed installed base volumes being up 7%, which is probably high. But I guess that service component is probably a big difference versus what people had expected previously. Could you maybe give us a bit more detail on how we should break those out, and how we should think about both the opportunity within that service opportunity and also just the runway for growth there over the next couple of years?
Continuing on that theme of expanding customer value, that spans multiple dimensions, and it covers just the core consumables for disinfectant. So growth did show up there. Then you have the ecosystem — our wipes plus clean probe covers — and we're seeing robust growth on that front. And honestly, that's a solid opportunity. I'd put it at roughly 30% of the existing installed base, or of customers who currently use that ecosystem. As awareness of its availability grows, there's a strong chance to expand there. As you mentioned, the service side is another major opportunity, and looking at service for the business overall, if I broke it out, I believe it was up more than 20% as well. On the whole, Sonic, CI, the core, would have been up perhaps 12% to 14%, while ecosystem, starting from a lower base, rose maybe around 25% to 30%. The drivers behind service are clearly twofold, with all the new install base coming in. That new install base, last in North America especially, came to about 940, and we expect similar figures in the second half. And broadly speaking, across the industry, perhaps 55% to 60% of customers sign up for service contracts, with the remainder on pay-as-you-go.
However, the larger factor behind service is the huge opportunity that exists in upgrades. So there are more than 10,000 upgrade opportunities when it comes to aged units out there. And the vast majority of those units that can be upgraded at present receive service from GE Healthcare. And when we do an upgrade, GE doesn't sell the upgrades. We sell them directly instead. What we've seen so far across all our upgrades is that even where people had service with GE before, they move over to Nanosonics. So there's a strong runway for continued service growth over quite a few years ahead.
Michael, is that the right way to think about it? From memory, service generally used to contribute around AUD 1,000 per annum — that was a while back, I think. Is that roughly how we should view it? When you sign those multi-service contract agreements, is the understanding — based on what Jason said earlier — that you receive a cash component upfront and then that revenue amortizes across the contract's life? Or could you give us some detail on those couple of things?
Exactly right. And those figures are approximate — roughly AUD 1,000 each year — and that includes every PM, plus any break-fix work and so on, along with parts for the customer. I should note there are also customers on pay as you go. So should a problem arise, they pay for it, and their rate might be higher. But regarding what Jason said about contract liabilities, since we provide service contracts of as long as six years, some customers choose to pay in advance for that full six-year service term. That explains why contract liabilities show roughly AUD 30 million, an increase of about 11%. So that represents cash still to come in over time. We amortize it across the life of the actual contract.
Second question, and this is a quick one for Jason, about the cost base going into the second half. Obviously, based on the guidance, it steps up somewhat from the first half as you ramp up for CORIS and other things, but you also mentioned that the ERP will obviously unwind. Jason, can you give us a bit of a feel here — if we look at that second half, I think the implied figure is around about 70 or 71, depending on which guidance you look at, at the midpoint for the second half. As we're sitting here today, is that a reasonable base to look at into FY 2026, or maybe just to give an idea of that plus the ERP, how should we think about the step up or the movement into 2026 on the cost base?
Sure — for the first half, like we mentioned, we've put roughly AUD 1.8 million, AUD 2 million into the ERP implementation. That should wrap up by the end of the second half of this year, so there'll be some additional OpEx from it in the second half. Looking ahead to 2026, our expectation is that this won't recur, since the system will be in place. Obviously there will still be some costs, I'd imagine, as we get familiar with the new ERP and system. But the bulk of that AUD 1.8 million we discussed having spent this half — we don't anticipate spending it in the first half of 2026.
On the implied kind of second half, though — that kind of run rate going into the second half, excluding maybe the ERP stuff — is it too early to give some context around that? I assume it depends on some of the timing around the CORIS release and commercialization, but I'm just trying to understand a little bit of what we're baking in, and any sort of direction or color on that would be super helpful.
With a business that's solely Trophon, the aim is to keep growing operating leverage in that area, and Jason is performing well on every cost-control front for that segment. Naturally, though, we'll be entering a launch phase for CORIS, which means added expenses will come with it. So the base is solid, yet I'd say there will be a substantial rise — not a leap in OpEx, but incremental growth on that front in the new year, allocated mostly toward CORIS.
Our next question comes from Shane Storey, who is on the line from Wilsons Advisory.
Just a couple of quick questions about capital sales and pricing to start. Jason, you mentioned that in EMEA, direct capital sales came in higher than MES capital sales. You also went into that in a bit more detail. I'm just wondering if that's a one-off we can sort of book and move on from, or if there's something structural in any of those markets that we need to think about.
It really comes down to what the customer prefers. And whether capital budgets are tight, or if there's some restraint, that will shape the path they take. But yeah, we wouldn't expect it to stay at such high levels. It'll move around a bit. That said, the biggest factor behind the revenue increase was North America, along with the fact that we sold more through that direct channel. North American units rose 100 units compared with the prior corresponding period. So that accounted for the great majority of it, offset by lower units in APAC, where we use a distributor. So as APAC goes down and North America goes up, you get that differentiation. So it's not price. Price is relatively stable for the period.
I believe I noticed a slight shift in pricing—a favorable one—in the US on a constant-currency basis. That caught me off guard, since upgrades make up a bigger part of the mix. I'm well aware that pricing on the PCP faced somewhat more pressure. Is that also what took place there?
When it comes to upgrade pricing, some trading activity does occur around upgrades as well. So typically you'll see volume discounts applied to upgrades. Broadly speaking, the pricing overall came out very, very similar.
One last question from me — just seeking clarity about how broad this initial de novo clearance for CORIS actually is. Am I right to assume that this first clearance will focus on a single scope category, and that it doesn't really matter which category it is — take duodenoscope as an example — and would I then also be correct to think that this would generally cover that class of scope, with Nanosonics subsequently working alongside all the various OEMs for that scope class? And as for the 510(k)s you mentioned, my assumption is that those pertain to other scope categories, say bronchoscopy or urology — again, just how should I think about those approvals?
This is tied to the category, though it can also tie to the brand. Now, regarding the brand, Olympus accounts for 80% of the market — but it is category related. Yet even inside a category, there are quite a number of different scopes. So what the FDA told us was to narrow, but very quickly — within roughly a 12 month window, we'd imagine covering closer to 70% of endoscope procedural volumes across the various categories.
Elyse Shapiro with Canaccord has our following question on the line.
Regarding the US manufacturing side, could you discuss how much margin improvement you're seeing there, and any CapEx that would be required to build out that facility or the inventory build?
As you're aware, consumables margins are already fairly high, and over time I'd expect us to build on that. Even an additional point or so, given the volume, could really add up. The CapEx we're investing, which of course gets depreciated over time, comes to roughly 3-plus million.
I'd say that's largely in hand at this point. You touched on some of the headway you've made in Japan, but at one stage you also mentioned a possible distribution setup in China. Is there anything new on that front? Have you run some sort of bake off or picked distributors for that market?
Our work on securing regulatory clearance in China is still moving forward, though progress there has slowed somewhat right now, and most of our attention is currently directed toward Japan.
Our next question comes from John Hester of Bell Potter, on the line.
Once 2025 has passed and you've finished approving the CORIS device, what ought we to anticipate regarding your continuing R&D expense, and which projects will that spending concentrate on?
What we're saying right now is that R&D expense should keep rising in absolute dollars, while falling as a share of revenue. We just went from 20% of revenue in PCP to 17%, and we'd expect that to drift down somewhat further. As for where the money goes, we're certainly not halting innovation in ultrasound reprocessing. A bit like your iPhone — they're on iPhone, I don't know, I probably still own the first one, but they're at roughly iPhone 16 now. Over time you'll see trophon3, 4s and 5s appear in that franchise too. With CORIS, we'll have our first generation. More will follow there. There's work ahead on expanded indications, et cetera. We're also directing some spending toward our digital traceability components, for CORIS and ultrasound alike, and that market is really starting to grow in importance. So the bulk of it lands across those three streams. Right now we're also examining, on an organic basis, areas beyond ultrasound and endoscopy, even though strong opportunities still exist in both of those categories.
So where else does it make sense to bring our know-how to bear, particularly when it comes to automating the manual steps that exist today around reprocessing reusable medical devices? If we spot an opportunity there that looks like a solid investment, my expectation is that a portion of that R&D spending would flow into that area too.
Let me put the question a different way, then: what portion of that R&D expense is internal or fixed cost? And second, why do you keep disclosing the trophon business's profitability separately if the R&D expense is plainly an ongoing part of the organization?
To start, I’m not certain I follow the latter portion of what you asked, but within the Trophon-only business, that segment by itself also covers all the R&D work we are carrying out in ultrasound reprocessing. And during the last half, that came to roughly AUD 6 million, compared with total R&D of around AUD 16 million in the first half. Out of that AUD 16 million, picture about AUD 10 million as being mostly tied to CORIS-related work or some digital-related work, mainly CORIS-related. So I believe it matters, though, for people to grasp that when we examine the trophon-only business through a profitability lens, it provides a signal of what is achievable in profitability once you are able to become standard of care. And as we showed, you can see that the Trophon-only business is a business that is quite profitable. And on an operating margin basis, reaching 27%, nearer to 30%, for the medical device industry, that is a pretty solid operating margin. So that is the reason we give that delta. But perhaps I misunderstood what you were asking, John.
Our following question comes from Richard Hemming, who is on the line with the Radar Report.
Over the years, Nanosonics has struck me as notably more resilient, and I've been particularly impressed by the way you've adjusted the business model somewhat. And at this point, given that you're generating positive cash flow and holding a fairly substantial cash balance, I've often asked myself why dividends aren't paid. What does the dividend policy actually say? To me, it's simply puzzling.
That's a fair question. I can tell you that our boards do review how we manage capital on a regular basis. From a franking standpoint, I think there isn't much of a benefit to dividends right now. And I think that accumulating that cash balance over the past several years has definitely made the organization more resilient. It gives us optionality regarding the investments we're able to make in ongoing growth initiatives without going back to the market. Product expansion—we're certainly interested in that as a strategy, but it doesn't always have to come organically. I know we've discussed this for a fair while, but we simply haven't succeeded in finding, yes, an acquisition target for our portfolio. And of course, some of that cash will be needed for overall CapEx requirements and for our working capital requirements, I should say, when we launch our CORIS. So it gives us that kind of resilience. But in future years, we would like to reach a position where we're able to pay dividends. I just think it's probably a little too early at the moment.
Up next, we have a question from Reece Frith of APSEC Funds Management.
Just a quick question about the M&A side of things. So you just mentioned cash flow and the cash balance. As you said, you brought on a dedicated resource in Europe, which was disclosed last half. I'd like to get a handle on the timing. You have CORIS that you're planning to launch, hopefully, in the second half of 2026. And that will consume a great deal of the business's attention over the next few years. So I suppose I'm questioning the timing of why you want to acquire something at this point, just to help square that with your CORIS work and what it's going to demand over the coming few years.
That's a great question, and it ties directly into the kind of M&A we'd pursue, particularly in the early going. As you're saying, we can't lose focus on the core growth drivers in front of us right now — the ongoing work with trophon and the integration of CORIS. If we can find something where you're not merely buying a product and folding it into the existing structure — where you're also adding new capabilities to the organization, along with the people who come with them — that's definitely something we'd consider. Thank you all for joining on what I know is a very busy day out there for results announcements, and I look forward to catching up with many of you alongside Jason over the coming week. Thank you very much.
Appreciate it. That brings today’s conference to a close. Thanks for taking part. You’re welcome to disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Nanosonics Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Nanosonics Limited earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.